Figma Shares Indicated To Open $105/$110
On Friday, Goldman Sachs analysts initiated coverage on Amneal Pharmaceuticals stock (NASDAQ: NASDAQ:AMRX) with a Neutral rating and set a price target of $12.00. The analysts highlighted the company’s strong product pipeline as a key driver of anticipated growth. According to InvestingPro data, the stock appears undervalued, with analyst targets ranging from $11 to $12, suggesting significant upside potential from current levels.
The analysts expect Amneal’s generics segment to exceed FactSet consensus estimates by approximately 13% in fiscal year 2027. This growth is expected to be fueled by the company’s focus on biosimilar and sterile injectable launches. Supporting this outlook, InvestingPro data shows strong revenue growth of ~13% over the last twelve months, with the company generating $2.8 billion in revenue. They noted Amneal’s track record of execution in various market environments and its strategic shift towards higher-value products, including injectables, inhalable devices, and biosimilars.
On the branded side, the analysts foresee growth above consensus expectations, driven by increased uptake of the recently launched Parkinson’s disease drug, Crexont. Their analysis is based on key opinion leader diligence, recent script data, and commercial execution. The analysts expect the branded segment to return to growth in fiscal year 2026, with contributions from Crexont, the endocrinology franchise, and the upcoming launch of Brekiya, a DHE auto-injector for migraines.
Goldman Sachs analysts also noted that they are approximately 7% above FactSet consensus estimates for revenue and 6% above for EBITDA in fiscal year 2027. They see potential for these estimates to expand further over time as the company continues its strategic focus. InvestingPro analysis reveals an "GREAT" overall financial health score, with particularly strong growth metrics. Discover more insights about Amneal’s financial health, including 6 additional ProTips and comprehensive valuation metrics, in the exclusive Pro Research Report.
In other recent news, Amneal Pharmaceuticals reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted EPS of $0.21, compared to the forecasted $0.15. The company reported revenue of $695 million, which was slightly below the anticipated $726.49 million. Despite this revenue shortfall, Amneal achieved a 5% year-over-year revenue growth, demonstrating resilience in a competitive market. Amneal’s gross margin improved to 43.1%, up 120 basis points from the previous year. In addition, the company announced the FDA approval of its Brekiya autoinjector for migraines, marking it as the first DHE autoinjector for this condition. This new product is expected to be available to patients in the second half of 2025. The company also highlighted strategic growth initiatives, including expansion in biosimilars and new product launches. Analysts from Piper Sandler and JPMorgan expressed interest in Amneal’s biosimilars and injectable segments, indicating potential for significant market opportunities. Amneal remains focused on expanding its product portfolio and expects to launch 20-30 new complex generic products annually.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.